CA3122640A1 - Treatment and prevention of glioblastoma - Google Patents
Treatment and prevention of glioblastoma Download PDFInfo
- Publication number
- CA3122640A1 CA3122640A1 CA3122640A CA3122640A CA3122640A1 CA 3122640 A1 CA3122640 A1 CA 3122640A1 CA 3122640 A CA3122640 A CA 3122640A CA 3122640 A CA3122640 A CA 3122640A CA 3122640 A1 CA3122640 A1 CA 3122640A1
- Authority
- CA
- Canada
- Prior art keywords
- adrenergic receptor
- use according
- day
- selective antagonist
- glioma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382917.5A EP3666266A1 (en) | 2018-12-12 | 2018-12-12 | Treatment and prevention of glioblastoma |
| EP18382917.5 | 2018-12-12 | ||
| PCT/EP2019/084822 WO2020120656A1 (en) | 2018-12-12 | 2019-12-12 | Treatment and prevention of glioblastoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3122640A1 true CA3122640A1 (en) | 2020-06-18 |
Family
ID=64746483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3122640A Pending CA3122640A1 (en) | 2018-12-12 | 2019-12-12 | Treatment and prevention of glioblastoma |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220008362A1 (https=) |
| EP (2) | EP3666266A1 (https=) |
| JP (1) | JP7746157B2 (https=) |
| CN (1) | CN113365619A (https=) |
| CA (1) | CA3122640A1 (https=) |
| ES (1) | ES2986469T3 (https=) |
| WO (1) | WO2020120656A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3048032A1 (es) * | 2025-05-27 | 2025-12-05 | Univ Madrid Complutense | N-(4-Ariloxi-3-hidroxibutan-2-il)alcanamidas con actividad antagonista adrenérgica beta-2 selectiva |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015121500A1 (en) * | 2014-02-17 | 2015-08-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical compositions for use in the treatment of ventilator-induced diaphragmatic dysfunction |
-
2018
- 2018-12-12 EP EP18382917.5A patent/EP3666266A1/en not_active Withdrawn
-
2019
- 2019-12-12 US US17/413,500 patent/US20220008362A1/en active Pending
- 2019-12-12 ES ES19829028T patent/ES2986469T3/es active Active
- 2019-12-12 CA CA3122640A patent/CA3122640A1/en active Pending
- 2019-12-12 JP JP2021534294A patent/JP7746157B2/ja active Active
- 2019-12-12 EP EP19829028.0A patent/EP3893861B1/en active Active
- 2019-12-12 WO PCT/EP2019/084822 patent/WO2020120656A1/en not_active Ceased
- 2019-12-12 CN CN201980091073.7A patent/CN113365619A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3893861B1 (en) | 2024-08-07 |
| CN113365619A (zh) | 2021-09-07 |
| JP2022517517A (ja) | 2022-03-09 |
| EP3893861C0 (en) | 2024-08-07 |
| JP7746157B2 (ja) | 2025-09-30 |
| ES2986469T3 (es) | 2024-11-11 |
| US20220008362A1 (en) | 2022-01-13 |
| WO2020120656A1 (en) | 2020-06-18 |
| EP3666266A1 (en) | 2020-06-17 |
| EP3893861A1 (en) | 2021-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107106580B (zh) | 治疗癌症干细胞的组合物 | |
| KR20200098536A (ko) | Dux4 발현과 관련된 질병의 치료를 위한 화합물 | |
| KR20150081422A (ko) | mTOR 경로 관련 질병 치료를 위한 화합물 | |
| JP7166021B2 (ja) | 癌の処置のためのドーパミンβ－ヒドロキシラーゼ（ＤＢＨ）阻害剤およびセロトニン受容体（５－ＨＴ）アンタゴニストの使用 | |
| EP3459537B1 (en) | Application of clofoctol for manufacturing pharmaceutical product for treating human neuroglioma | |
| JP6483736B2 (ja) | 癌の治療のためのキナーゼ阻害剤 | |
| US20190336485A1 (en) | Azophenols as ERG Oncogene Inhibitors | |
| EP3893861B1 (en) | Treatment and prevention of glioblastoma | |
| CN113368249A (zh) | 一种ogt抑制剂及其用途 | |
| JP6489517B2 (ja) | ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬 | |
| Sánchez-Puelles et al. | Treatment and prevention of glioblastoma | |
| WO2023133414A2 (en) | Selective elimination of senescent cells by ferroptosis induction | |
| KR102436309B1 (ko) | 암의 예방 또는 치료용 약학적 조성물 | |
| KR101800129B1 (ko) | 암의 예방 또는 치료용 약학적 조성물 | |
| WO2010087107A1 (ja) | メラノーマの転移抑制剤 | |
| US20250312300A1 (en) | Bridged bicyclic carboxylic acids for treating osteosarcoma and ewing sarcoma | |
| US20250049773A1 (en) | Inhibition of sterol response element binding proteins as atarget for selective elimination of senescent cells | |
| CA3072389C (en) | Selective beta2-adrenergic receptor antagonist for treating von hippel-lindau disease | |
| EP3664788B1 (en) | Compounds for treating von hippel-lindau disease | |
| KR101941045B1 (ko) | 암의 예방 또는 치료용 약학적 조성물 | |
| CN121398819A (zh) | 应用于治疗实体瘤中的5-htr1b调节剂 | |
| WO2015181628A1 (en) | Treatment of acute myeloid leukemia with an hck inhibitor | |
| HK1241730A1 (en) | Composition for treating cancer stem cells | |
| HK1205500B (en) | Kinase inhibitors for the treatment of cancer | |
| HK1153938A1 (en) | Use of a cdk inhibitor for the treatment of glioma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230712 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240924 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241227 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241227 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250122 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250220 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250704 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250704 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250916 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250916 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251205 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251205 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE Effective date: 20260115 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT Effective date: 20260413 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260413 |